MX2023002570A - Terapia de combinacion de un antagonista de pd-1 y un antagonista para vegfr-2 para tratar a pacientes con cancer. - Google Patents

Terapia de combinacion de un antagonista de pd-1 y un antagonista para vegfr-2 para tratar a pacientes con cancer.

Info

Publication number
MX2023002570A
MX2023002570A MX2023002570A MX2023002570A MX2023002570A MX 2023002570 A MX2023002570 A MX 2023002570A MX 2023002570 A MX2023002570 A MX 2023002570A MX 2023002570 A MX2023002570 A MX 2023002570A MX 2023002570 A MX2023002570 A MX 2023002570A
Authority
MX
Mexico
Prior art keywords
antagonist
cancer
vegfr
breast cancer
combination therapy
Prior art date
Application number
MX2023002570A
Other languages
English (en)
Spanish (es)
Inventor
Weon Sup Lee
Jin- San Yoo
Seon Young Lee
Sang Ryeol Shim
Original Assignee
Pharmabcine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmabcine Inc filed Critical Pharmabcine Inc
Publication of MX2023002570A publication Critical patent/MX2023002570A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2023002570A 2020-09-02 2021-09-02 Terapia de combinacion de un antagonista de pd-1 y un antagonista para vegfr-2 para tratar a pacientes con cancer. MX2023002570A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063073512P 2020-09-02 2020-09-02
US202063122321P 2020-12-07 2020-12-07
PCT/IB2021/058043 WO2022049526A1 (en) 2020-09-02 2021-09-02 Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer

Publications (1)

Publication Number Publication Date
MX2023002570A true MX2023002570A (es) 2023-05-19

Family

ID=77914405

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002570A MX2023002570A (es) 2020-09-02 2021-09-02 Terapia de combinacion de un antagonista de pd-1 y un antagonista para vegfr-2 para tratar a pacientes con cancer.

Country Status (8)

Country Link
US (1) US20230265196A1 (https=)
EP (1) EP4208482A1 (https=)
JP (1) JP2023540490A (https=)
KR (1) KR20230087451A (https=)
AU (1) AU2021337223A1 (https=)
CA (1) CA3189987A1 (https=)
MX (1) MX2023002570A (https=)
WO (1) WO2022049526A1 (https=)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP2002531466A (ja) 1998-12-01 2002-09-24 プロテイン デザイン ラブス， インコーポレイテッド γ−インターフェロンに対するヒト化抗体
SI1916001T1 (sl) 2002-03-04 2011-10-28 Imclone Llc Äśloveĺ ka protitelesa specifiäśna za kdr in njihova uporaba
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CN102203132A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂的组合物和使用方法
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
ES2676205T3 (es) 2011-03-31 2018-07-17 Merck Sharp & Dohme Corp. Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados
JP6238459B2 (ja) 2011-08-01 2017-11-29 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
JP6742903B2 (ja) 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
MY184154A (en) 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
US20190183972A1 (en) * 2016-06-03 2019-06-20 Imclone Llc Combination of ramucirumab and pembrolizumab for the treatment of certain cancers

Also Published As

Publication number Publication date
WO2022049526A1 (en) 2022-03-10
US20230265196A1 (en) 2023-08-24
EP4208482A1 (en) 2023-07-12
CA3189987A1 (en) 2022-03-10
KR20230087451A (ko) 2023-06-16
AU2021337223A1 (en) 2023-03-16
JP2023540490A (ja) 2023-09-25

Similar Documents

Publication Publication Date Title
Dey et al. PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials
Jackisch et al. Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars
Brana et al. Locally advanced head and neck squamous cell cancer: treatment choice based on risk factors and optimizing drug prescription
WO2020176693A3 (en) Methods for treating map3k8 positive cancers
Darvishi et al. Recent progress in cancer immunotherapy: Overview of current status and challenges
Singh et al. Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma: a pilot study
Kubicek et al. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies
Yan et al. 3D mathematical modeling of glioblastoma suggests that transdifferentiated vascular endothelial cells mediate resistance to current standard-of-care therapy
Xue et al. Dose-volume effects on brainstem dose tolerance in radiosurgery
Wang et al. Mitochondrial stress adaptation promotes resistance to aromatase inhibitor in human breast cancer cells via ROS/calcium up-regulated amphiregulin–estrogen receptor loop signaling
MX2025004433A (es) Combinaciones de un degradador selectivo del receptor de estrogenos (serd) para el tratamiento del cancer
MX2021002241A (es) Uso de linfocitos infiltrantes de tumor para tratar pacientes con carcinoma de pulmón de células no pequeñas (nsclc) refractario al anticuerpo anti muerte programada 1 (pd-1).
Vitzthum et al. Comparison of hematologic toxicity and bone marrow compensatory response in head and neck vs. cervical cancer patients undergoing chemoradiotherapy
Russe et al. Autologous fat grafting for enhancement of breast reconstruction with a transverse myocutaneous gracilis flap: a cohort study
MX2023002570A (es) Terapia de combinacion de un antagonista de pd-1 y un antagonista para vegfr-2 para tratar a pacientes con cancer.
Wobb et al. Comparison of chronic toxicities between brachytherapy-based accelerated partial breast irradiation and whole breast irradiation using intensity modulated radiotherapy
Parikh et al. Linear accelerator-based flattening-filter-free stereotactic radiosurgery for trigeminal neuralgia: Feasibility and patient-reported outcomes
MX2023003032A (es) Terapia de combinacion de un antagonista de pd-1 y un antagonista de lag3 y lenvatinib o una sal farmaceuticamente aceptable del mismo para el tratamiento de pacientes con cancer.
MX2025009446A (es) Erdafitinib para administración intravesical para usar en el tratamiento del cáncer de vejiga
Gmeiner et al. F10 inhibits growth of PC3 xenografts and enhances the effects of radiation therapy
Stone et al. Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity?
TW200610555A (en) Extended treatment of tumors through vessel occlusion with light activated drugs
MX2024007015A (es) Inhibidor de cdk4 y 6 en combinacion con fulvestrant para el tratamiento del cancer de mama avanzado o metastasico con receptor hormonal positivo y receptor 2 del factor de crecimiento epidermico humano negativo en pacientes tratados anteriormente con un inhibidor de cdk4 y 6.
Flynn Higher dose radiotherapy trial halves treatment time
Stevenson Oral cavity cancer treatment protocols